Over-The-Counter (OTC) Veterinary Drugs Market projected to expand at a CAGR of 8.1% 2022-2032

Global Over-The-Counter (OTC) Veterinary Drugs market is expected to grow at a decent rate owing it to the increase in number of manufacturers for Over-The-Counter (OTC) veterinary drugs, worldwide. There are variety of drugs available in the market as Over-The-Counter (OTC) veterinary drugs for the safe use in animals. These drugs are available in various forms, topical drugs are available as gels, oils, creams, and sprays for various applications. Antibiotics and non-steroidal anti-inflammatory drugs are very common Over-The-Counter (OTC) veterinary drugs in the market. The drugs are available for various medical conditions related with the skin, eyes, and allergic reactions to the animals.

The Over-The-Counter (OTC) veterinary drugs market is well equipped with the retail pharmacies by the end user segment. Injectable drug involve vaccines, which are majorly used by the companion animals for their safety and improving their well-being. The Over-The-Counter (OTC) veterinary drugs market is expected to propel during the forecast period with the growing awareness on the safety and prevention of diseases among companion animals.

Over-The-Counter (OTC) Veterinary Drugs, also termed as non-prescription drugs are drugs that are available without any prescription. These drugs are effective and safe when all the directions on the label or directed by the healthcare professional are followed. The FDA in the U.S. considers when a specific drug is effective and safe enough to be sold over-the-counter. Over-the-counter (OTC) veterinary drugs usage is attributable to the savings on cost incurred on clinical visit and on the drug cost. There are limited veterinary drugs that are approved and available to veterinarians.

Request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-9190

The veterinarians often depend on the use of different sources and types of drugs to treat their patients. Over-The-Counter (OTC) veterinary drugs are checked on the assurance of the product effectiveness, safety, and manufacturing to stringent standards for purity, quality, and potency. The FDA Centre for Veterinary Medicine (CVM) is responsible for the manufacturing and distribution of veterinary food additives and drugs. Over-The-Counter (OTC) veterinary drugs are regulated under The Federal Food, Cosmetic, and Drug ACT, which regulated statutory provisions that govern all the key regulations of Over-The-Counter (OTC) veterinary drugs. The Act formulate drugs as, “articles for use in the cure, diagnosis, treatment, mitigation, or prevention of diseases in animals or man”.

Over-The-Counter (OTC) Veterinary Drugs Market: Drivers and Restraints-

Over-The-Counter (OTC) Veterinary Drugs are poised to witness a significant growth owing it to the paradigm shift from Rx to OTC by major pharmaceutical manufacturers. Increasing tendency of people towards the health of their companion animals in developed regions, majorly, and immense cost savings with Over-The-Counter (OTC) veterinary drugs pose various advantages, further boosting demand for Over-The-Counter (OTC) veterinary drugs.

However, several serious issues with OTC drugs pertaining to inappropriate substance abuse vehemently and diagnosis of the animal might obstruct market growth for Over-The-Counter (OTC) veterinary drugs during the forecast timeframe. This has also resulted in withdrawal of various Over-The-Counter (OTC) veterinary drugs used for therapy from the market over the years. Stringent regulations regarding Over-The-Counter (OTC) veterinary drugs and substance abuse related issues might also hinder market growth for Over-The-Counter (OTC) veterinary drugs during the forecast period.

Over-The-Counter (OTC) Veterinary Drugs Market: Region-wise Outlook

Over-The-Counter (OTC) veterinary drugs market is immensely concentrated in major developed economies like the U.S., Japan, and China. The United States is expected to witness a moderate growth due to market saturation in a few product categories. Technological advancements is however, expected to boost market growth for Over-The-Counter (OTC) veterinary drugs worldwide.

Increase in consumer appetite for Over-The-Counter (OTC) veterinary drugs for their companion animals, and growing need of curbing the veterinary-related healthcare costs is expected to fuel the market growth for Over-The-Counter (OTC) veterinary drugs in the Europe region. Increase in efforts for Over-The-Counter (OTC) veterinary drugs licensing for treatment of various diseases in animals is also expected to boost the market growth for Over-The-Counter (OTC) veterinary drugs during the forecast period. However, traditional medications for veterinary disease treatment might slow down the market growth for Over-The-Counter (OTC) veterinary drugs in the Asia-Pacific and MEA region.

Over-The-Counter (OTC) Veterinary Drugs Market: Key Market Participants

Some of the market participants in the Global Over-The-Counter (OTC) Veterinary Drugs market identified across the value chain include: Merck & Co., Inc., Zoetis, Inc., Eli Lilly and Company, Virbac, Bayer AG, Sanofi, Vetoquinol S.A., Boehringer Ingelheim International GmbH, and Dechra Pharmaceuticals PLC.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-9190

The report covers exhaust analysis on:

  • Market Segments
  • Market Dynamics
  • Market Size
  • Supply & Demand
  • Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Technology
  • Value Chain

Regional analysis includes:

  • North America (U.S., Canada)
  • Latin America (Mexico. Brazil)
  • Western Europe (Germany, Italy, France, U.K, Spain)
  • Eastern Europe (Poland, Russia)
  • Asia Pacific (India, ASEAN, Australia & New Zealand)
  • China
  • Japan
  • Middle East and Africa (GCC Countries, S. Africa, Northern Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Over-The-Counter (OTC) Veterinary Drugs Market: Segmentation

On the basis of Drug Class, Over-The-Counter (OTC) Veterinary Drugs Market can be segmented as:

  • H2 Receptor Antagonists
  • Non-steroidal Anti-inflammatory Drug
  • Artificial Tears and Ocular Lubricants
  • Antihistamine
  • Antibacterial
  • Glucocorticosteroid
  • Antidiarrheal Agents
  • Nutraceuticals
  • Others

On the basis of Form, Over-The-Counter (OTC) Veterinary Drugs Market can be segmented as:

  • Topical
  • Oral
  • Injectable

On the basis of Distribution Channel, Over-The-Counter (OTC) Veterinary Drugs Market can be segmented as:

  • Retail Pharmacies
  • Mail-order Pharmacies
  • Hypermarkets & Supermarkets

On the basis of geography, Over-The-Counter (OTC) Veterinary Drugs Market can be segmented as:

  • North- America
  • Eastern Europe
  • Western Europe
  • Asia-Pacific excluding China & Japan
  • China
  • Japan
  • Middle East and Africa
  • Latin America

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-9190

Report Highlights:

  • Detailed overview of parent market
  • Changing market dynamics in the industry
  • In-depth market segmentation
  • Historical, current, and projected market size in terms of volume and value
  • Recent industry trends and developments
  • Competitive landscape
  • Strategies of key players and products offered
  • Potential and niche segments, geographical regions exhibiting promising growth
  • A neutral perspective on market performance
  • Must-have information for market players to sustain and enhance their market footprint

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 8-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006, Jumeirah Bay 2, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedInTwitterBlogs

PD-1/PD-L1 inhibitors Market value of US$ 43.7 Billion in the year 2022 | FMI

PD-1/PD-L1 Inhibitors Market: Dynamics

PD-1/PD-L1 Inhibitors market is among the highest growing field in the pharmaceutical industry. PD-1/PD-L1 Inhibitors promise improved survival of patients, with low toxicity which is a huge market driving factor. The products available in the market for PD-1/PD-L1 inhibitors are increasingly meeting safety standards and are effective in the treatment of cancers. However, experts believe that the molecules in early clinical studies point towards safety concerns and high development cost can lead to high prices of the drug in the market which are a few challenged pharmaceutical companies have to encounter.

For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-12644 

PD-1/PD-L1 Inhibitors Market Overview

Immunotherapy treatment methods are evolving and are one of the prime methods for the treatment of cancer. PD-1/PD-L1 inhibitors have a targeted approach and decrease toxicity and hence resulting in increased efficacy. PD-1/PD-L1 inhibitors market is achieving advancements owing to the efficiency of the treatments.

PD-1/PD-L1 Inhibitors have been useful in the treatment of several cancers. PD-1/PD-L1 Inhibitors are being studies for the treatment of various type of cancers.

PD-1/PD-L1 Inhibitors Market: Region-wise Outlook

Based on geography, the PD-1/PD-L1 inhibitors market can be segmented into five major regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa. At present, North America holds a leading position in the PD-1/PD-L1 inhibitors market followed by Europe. The major driving factors which have driven the growth of the PD-1/PD-L1 inhibitors market in these regions are constantly increasing the prevalence of various types of cancers, and demand for technologically advancements in the already successful approaches for treatment. The major companies are focusing on second generation therapies to improve the current treatment scenario with PD-1/PD-L1 inhibitors.

For Information On The Research Approach Used In The Report, Request TOC@ https://www.futuremarketinsights.com/toc/rep-gb-12644 
Following North America, European countries are also anticipated to show steady growth in the PD-1/PD-L1 inhibitors market. In the next few years, Asia-Pacific would show remarkable growth in the PD-1/PD-L1 inhibitors market as it is developing at a very rapid pace and has shown the emergence of many regional players. The factors which would fuel the growth of PD-1/PD-L1 inhibitors market in Asia-Pacific are increasing awareness regarding various types of cancers, increase the number of patients getting affected with the disease, and rapid development of the healthcare infrastructure across the Asian countries. PD-1/PD-L1 inhibitors market would evolve at a rapid rate across the regions. However, North America would maintain its position in the overall PD-1/PD-L1 inhibitors market.

PD-1/PD-L1 Inhibitors Market: Key Players

It is expected that with due course of time, there will be an entry of multiple pharmaceutical players in the PD-1/PD-L1 inhibitors market as PD-1/PD-L1 inhibitors have witnessed good investments from various key pharmaceutical companies. PD-1/PD-L1 inhibitors market currently has multiple ongoing deals and active research with many pharmaceutical companies looking to launch there products. Some of the top players operating in the PD-1/PD-L1 Inhibitors Market are Bristol-Myers Squibb, Merck & Co., F. Hoffmann-La Roche AG, Sanofi, Amgen, Gilead Sciences, AstraZeneca, Novartis, Pfizer, Celgene and many others.PD-1/PD-L1 Inhibitors Market has the presence of many regional players which have a huge market share in emerging countries.

The report covers exhaust analysis on:

  • Market Segments
  • Market Dynamics
  • Market Size
  • Supply & Demand
  • Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Technology
  • Value Chain

The regional analysis includes:

  • North America (U.S., Canada)
  • Latin America (Mexico. Brazil)
  • Western Europe (Germany, Italy, France, U.K, Spain)
  • Eastern Europe (Poland, Russia)
  • Asia-Pacific (China, India, ASEAN, Australia & New Zealand)
  • Japan
  • The Middle East and Africa (GCC Countries, S. Africa, Northern Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 9-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedInTwitterBlogs

Acute Kidney Injury Treatment Market is expected to witness staggering growth, registering 8.2% CAGR from (2022-2029)

[230 Pages Report] Growing prevalence of acute kidney injury as well as increasing early diagnosis with subsequent increasing treatment seeking rate are the prime drivers of the global acute kidney injury treatment market. Treatment such as dialysis therapies has resulted in better management of acute kidney injury, and has helped reduce the risk of various kidney-related diseases.

Various organisations are involved in acute kidney injury disease surveillance. In 2021, China’s central government issued the 13th Five Year National Science and Technology Innovation Plan, which aims to create a national platform to share biomedical big data, develop technologies for precision medicine, and integrate them into a multilevel knowledge database, leading the healthcare treatment market to new growth avenues.

The global acute kidney injury treatment market is projected to exhibit a noteworthy 8% CAGR over the forecast period (2022–2029).

“Increasing prevalence of acute kidney injury across the world and increasing number of dialysis centers are prominent factors augmenting the growth prospects of the global acute kidney injury treatment market.”

Key Takeaways of Acute Kidney Injury Treatment Market Study

  • Owing to increasing acute kidney injury prevalence, number of dialysis centers, and efficient treatment method, the dialysis segment is expected to be a significant revenue generator.
  • The intermittent hemodialysis segment, under product, in the acute kidney injury treatment market, is expected to be a prominent segment, as results provided by this treatment are more efficient as compared to other dialysis methods.
  • The pre-renal injury segment is anticipated to dominate the acute kidney injury treatment market, as pre-renal injury is more prevalent in patients with acute kidney injury.
  • North America is expected to dominate the global acute kidney injury treatment market in terms of revenue, owing to the growing adoption of advanced treatments over conventional methods. East Asia is expected to offer lucrative opportunities for the acute kidney injury treatment market during the forecast period.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-14403

acute kidney injury treatment market

Advanced Technology & Product Launches – Key Strategies Followed by Manufacturers

Advancements in diagnostic technology and more product availability in order to streamline their product offerings in respective regions with diverse product portfolios are being followed by players in the acute kidney injury treatment market. For instance, in January, 2022, Fresenius Medical Care launched the 4008A dialysis machine to improve accessibility to life-sustaining dialysis treatment.

More Valuable Insights on Acute Kidney Injury Treatment Market

Future Market Insights brings a comprehensive research report on forecast revenue growth at global, regional, and country levels, and provides an analysis of the latest industry trends in each segment from 2014 to 2029. The global acute kidney injury treatment market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the readers.

The study provide compelling insights on the acute kidney injury treatment market on the basis of product (dialysis and drug therapy), injury (pre-renal injury, intrinsic renal injury, and post-renal injury), and distribution channel (hospitals, ambulatory surgical centers, and others), across seven major regions.

Acute Kidney Injury Treatment Market By Category Product :

  • Dialysis
    • Intermittent Hemodialysis
    • Continuous Renal Replacement Therapy (CRRT)
    • Sustained Low Efficiency Dialysis (SLED)
  • Drug Therapy
    • Antibiotics
    • Diuretics
    • Immunosuppressive Agents

Injury :

  • Pre-renal Injury
  • Intrinsic Renal Injury
  • Post-renal Injury

Distribution Channel :

  • Hospitals
  • Ambulatory Surgical Centers
  • Others

 Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-14403

Region :

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • MEA

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedInTwitterBlogs

ePharmacy Market to be worth US$ 177.7 Bn by 2026 | CAGR of 16.5% , Get Insights FMI

[311 Pages Report] According to a recent study done by FMI, the ePharmacy market is expected to reach US$ 329.83 billion by 2032, up from US$ 69.8 billion in 2021, expanding at a high CAGR of 16.5%. This study explains how  the ePharmacy market is directly proportional to the increasing penetration of internet-based pharmacy in the world market coupled with rising awareness of epharmacy amongst the common masses. 

Easy purchasing, availability of a range of medications and quality medical services on the internet is holding up the customer preferences and shifting them to e pharmacy platforms.   

Get Sample Report @ https://www.futuremarketinsights.com/reports/sample/14334

A large number of smartphone sales and spreading awareness about the concept of epharmacy. The rising geriatric population base that suffers from chronic diseases and staying in remote areas increases sales through ePharmacy. This also affects the e-pharmacy market in India as sales of smartphones are increasing here as well.  

Lucrative offers, high discounts, and easy accessibility help end users navigate and order medicines easily, part of the ePharmacy business model. This drives the global market and increases sales through epharmacy.  

With the increasing accessibility of e-commerce and the online industry, the availability of medicines is also rising as multiple vendors (B2C and B2C) are getting a space online. This provides these vendors with a better space to sell their products.   

The major challenge with ePharmacy market is rising number of illegal vendors online that decrease the credibility of online sources. Also, risks associated with counterfeit drugs are downgrading the marketing. To prevent these illegal vendors, e pharmacy regulations are there in every country.”

Ask An Analyst @ https://www.futuremarketinsights.com/ask-the-analyst/14334 

Key Takeaway 

  • The government initiatives and e pharmacy regulations support and control digital technology to improve the space and its functionality. Several industry players get benefitted from the government awareness programs.  
  • North America dominates the market as it holds more than 35% of the global epharmacy market. The factor behind the excessive growth is the extreme internet penetration amongst the American population.  
  • epharmacy businesses design their product profile and marketing campaign with the prescription portal attached to it that makes customers interact with the website easily and upload the prescription without a hitch.  
  • 63% of the world’s population is on the internet and interacts with eCommerce websites daily which directly proliferates the market growth.  
  • The global epharmacy market is segmented by product type that is further segmented into OTC products and prescription medicines.  
  • The biggest segment by the product type category is OTC products. These products are in high demand because of the easy access and low hassle processes.  

Competitive Landscape 

The Walgreen Company dominates the global ePharmacy marketExpress Scripts Holding, CVS Health, DocMorris, Giant Eagle, Wal-Mart Stores, OptumRx, PharmEasy, 1mg and Netmeds. These companies are adopting new digital channels and processes to increase their stronghold in the ePharmacy market. 

  • In 2021, PharmEasy  initiated the takeover of MedLife to expand the deliverables and stronghold in India.
  • Lately, Express scripts have launched a new program named Express Scripts Parachute Rx that offer price discounts on multiple products. 

Buy Complete Report @ https://www.futuremarketinsights.com/checkout/14334

Key Market Segments

By Product Type:

  • OTC products
  • Prescription medicine

Explore Wide-ranging Coverage of FMI’s Healthcare Landscape

Pharmacy Refrigerators Market

Pharmacy And Drug Store Franchises Market

Pharmacy Automation Systems Market

Blood Warmer Devices Market

Hydrokinetic Fibre Dressings Market

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries:sales@futuremarketinsights.com
Browse All Reports : https://www.futuremarketinsights.com/reports
LinkedInTwitterBlogs

Acetaminophen Market Worth US$ 14.07 Billion by 2031 – Get Insights FMI

[332 Pages Report] According to a recent study by Future Market Insights (FMI), the global acetaminophen market is expected to grow from US$ 9.4 Bn in 2021, to over US$ 14.1 Bn by 2031, expanding at a 4.1% CAGR over the forecast period 2021-2031.

Acetaminophen/ paracetamol is widely being adopted by individuals and healthcare providers and are sold over the counter, which is boosting sales in the market.  Paracetamol is widely consumed as it is suitable to all age groups i.e. adults, children’s, pediatrics and geriatrics to treat mild to moderate pain. Paracetamol is the most efficient and safe drug to manage pain when consumed in a controlled dosage.

The most prescribed OTC (over the counter) drug is acetaminophen, which is widely used as the first line of treatment. As chronic disorders have symptoms of pain, demand is projected to increase over the forecast period.

Request Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-14325

According to the CDC, in 2019, 20.4% of adults had chronic pain and 7.4% of adults had chronic pain that frequently limited life or work activities. Similarly, in the U.K., around 26% of patients with diabetes were found to have peripheral neuropathic pain. Paracetamol can be combined with other pain management drugs that are sold through prescription only, which is expected to continue boosting sales.

Further, increasing awareness regarding palliative care in terminally ill patients is boosting the adoption of analgesics for pain management. Since the prevalence of pain is over 75% in advanced disease conditions, sales are expected to gain traction in the forthcoming years.

In the U.S., palliative care services are delivered following government and commercial reimbursement policies. Hospital palliative care programs in the U.S. include palliative care consultation teams and dedicated in-patient care units. Non-hospital palliative care programs include ambulatory care, and office and home-based palliative care programs.

Healthcare companies are collaborating with healthcare professionals, healthcare service providers, and hospitals to improve quality care for the patients. In addition to this, manufacturers are investing in product development to improve sales in the market. For instance, in 2020, Haihe Pharmaceutical Co. Ltd. outsourced the China rights to its non-opioid analgesic candidates, RMX-1001 and RMX-1002, to 3D Biomedicine Science & Technology Co. Ltd.

Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-14325

global acetaminophen market

Key Takeaways:

  • Based on product type, the acetaminophen segment is projected to growt at a 4.1% CAGR through 2031.
  • The oral route of administration segment accounted for 92.4% of the total market share in 2021.
  • In terms of sales type, the OTC (over the counter) segment accounted for 91.6% of the global market share in 2021.
  • Sales through retail pharmacies will continue gaining traction. In 2021, the segment accounted for 28.5% of the total market share.
  • North America held the largest share of 33.0% of the global acetaminophen market in 2021, and the trend is expected to continue over the assessment period.

“Growing demand for self-aid and cost-effective OTC pain relievers, along with increasing usage of acetaminophen as the first line of treatment for pain management are the key factors projected to drive the market in the forthcoming years,” says the FMI analyst.

Competition Landscape

Leading players operating in the global acetaminophen market are Abbott, Janssen Pharmaceuticals, Inc. [Johnson & Johnson], Bristol-Myers Squibb and Company, Cardinal Health Inc., Viatris, Procter & Gamble Company, Sanofi, Novartis AG, Bayer AG, Teva Pharmaceutical Industries Ltd, Perrigo Company, Mallinckrodt Pharmaceuticals, Glaxo SmithKline Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd, and Sun Pharmaceutical Industries Ltd.

Some of the leading companies of the acetaminophen market are focusing on product launch collaboration and partnership strategies for global expansion objectives, thereby, enhancing their market presence. For instance:

  • Johnson & Johnson, In March 2020,  announced that it will be boosting up production of its flagship product Tylenol which is an over-the-counter pain killer
  • GlaxoSmithKline, In February 2020 was approval by the Food and Drug Administration for Advil Dual Action, with acetaminophen as an over-the-counter (OTC) product for pain relief.

Buy Now/Purchase @ https://www.futuremarketinsights.com/checkout/14325

More Insights into Acetaminophen Market Report

Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031. The global acetaminophen market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

The study provides compelling insights into the acetaminophen market. The Market is segmented into four parts based on product (acetaminophen, acetaminophen with opioids, others) based on the route of administration (oral, injectable, others) based on sales type (OTC (over the counter) and RX (prescription) based on the distribution channel (hospital pharmacies, retail pharmacies, drug stores, e-commerce, others) and across seven major regions.

Acetaminophen Market By Category Product Type :

  • Acetaminophen
  • Acetaminophen with Opioids
  • Others

Route of Administration :

  • Oral
  • Injectable
  • Others

Sales Type :

  • OTC (Over-the-counter)
  • Rx (Prescription)

Distribution Channel :

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • E-commerce
  • Others

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedInTwitterBlogs

Medical Rehabilitation Robotics Market is expected to reach US$ 1.4 Billion by 2031 | FMI

[406 Pages Report] As per a recent market analysis by Future Market Insights (FMI),  the global medical rehabilitation robotics market was valued at over US$ 264.0 Mn in 2020 and is projected to expand at a stupendous 15.9% CAGR over the forecast period.

Increasing development of robotic products and devices that have the ability to perform a wide array of tasks is propelling sales in the market. Surgical robots are developed for the purpose of assisting surgeons in operating on a varied range of procedures, which in turn is improving patient outcomes.

Request Sample Copy of Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-14242

The designing and development of automated robotic models for rehabilitation and assistive services and applications have led to an advancement in disease recovery term. Rising awareness regarding the use of medical rehabilitation robotics for patients with disabilities, as well as for cognitive and behavioral disorders is spurring demand in the market.

The growth in rehabilitation therapy and integrated robotics has increased research and development activities associated with their applications in home-based settings. In comparison with clinical therapy, home therapy has the potential to augment standard care and enable a consistent treatment regime by increasing the frequency and duration of training sessions.

Carrying out rehabilitation services at home offers convenience and comfort. Growing preference for affordable, convenient, and time-saving robotic devices over other therapy devices in hospitals settings is expected to augment the growth of the market.

The development of medical rehabilitation robotics market is reliant on increasing healthcare spending, rising research and development activities, larger government-backed funding, and rising initiatives to promote the utility of rehabilitation robots

Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-14242

Key Takeaways:

  • Based on product type, demand in the therapeutic/assistive products is expected to account for 71.8% of the total market share in 2031, growing at a 15.4% CAGR.
  • In terms of extremity, the upper extremity segment is expected to hold 54.8%of the total market share by 2031.
  • Sales in the limb motility segment are projected to grow at a 15.9% CAGR through 2031.
  • In terms of patient type, the adults segment held 86.9% of the total market share in 2020, and the trend is expected to continue over the forecast period.
  • Applications in the neurorehabilitation segment are projected to account for a substantial share in the global medical rehabilitation robotics market.
  • Rehabilitation centers held the largest value share of 47.7% in 2020. However, hospitals are expected to account for 36.9% of the total market share by 2031.

“The integration of automation and assistive technology in medical equipment, along with surging demand for artificial intelligence (AI) based robotics in rehabilitation centers will continue boosting the market over the forecast period,” says an FMI analyst.

Competition Landscape

Leading players operating in the market are investing in acquisitions, mergers, expansion, and the development of an extensive clinical pipeline to improve sales in the market. Besides this, players are expandingtheir product portfolios to increase their consumer base. For instance:

  • In October 2021, Fourier Intelligence was selected and awarded the Top 4 Leading Rehabilitation Technology Enterprise by KPMG and the China Association of Non-Public Health Institutions, co-organized by the Health Sector Strategy at an event that was held in Shanghai.
  • In December 2020, Anthrtonix DANA, a telehealth tool by AnthroTronix, was used at the Johns Hopkins Hospital to identify and monitor cognitive deficits and recovery of COVID-19 patients.

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-14242

What Does the Report Cover?

Future Market Insights offers a unique perspective and actionable insights on the medical rehabilitation robotics market in its latest study, presenting historical demand assessment of 2016 – 2020 and projections for 2021 – 2031.

The research study is based on the Product – (Exoskeletons and Therapeutic/ Assistive), Extremity- (Upper Extremity and Lower Extremity), Therapy Type (Limb Mobility, Gait and Sensory), Patient Type (Adult and Paediatric), Application (Neurorehabilitation, Physical Rehabilitation and Others) and End User (Hospitals, Wellness Centers, Rehabilitation Centers and Homecare) across seven key regions of the world.

Future Market Insights’ Expertise in Life Sciences and Transformational Health

Our expert team of industry analysts comprising management graduates, medical professionals, engineers, and project managers provides insights on emerging therapy areas, diagnostic tools, medical devices and components, reimbursement and market access, biotechnology, and life science research products and services to equip decision-makers with sound inputs and strategic recommendations. Click here to learn more about how we zero in on the critical aspects of this industry.

Medical Rehabilitation Robotics Market By Category

Product:

  • Exoskeletons
  • Therapeutic/ Assistive

Therapy Type:

  • Limb Mobility
  • Gait
  • Sensory

Extremity:

  • Upper Extremity
  • Lower Extremity

Patient Type:

  • Adults
  • Paediatric

Application:

  • Neurorehabilitation
  • Physical Rehabilitation
  • Others

End User:

  • Hospitals
  • Wellness Centers
  • Rehabilitation Centers
  • Homecare

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa (MEA)

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 9-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedInTwitterBlogs

Nasal Antihistamines Market is projected to total US$ 3.0 Billion by 2031 | Says FMI

According to a recent study by Future Market Insights (FMI), the nasal antihistamines market is expected to witness steady growth during the forecast period. The market valuation is expected to increase from US$ 1.89 Bn in 2020 to over US$ 3.08 Bn by 2031. This reflects a cumulative CAGR of around 3.1% over the forecast period (2021-2031).

Antihistamines are a class of medications that are often used to treat allergy symptoms. These medications are used to treat problems caused by an excess of histamine, a substance produced by the immune system. People who are allergic to pollen and other allergens are the most prevalent users of antihistamines. Sneezing, congestion, and itchy, runny nose can all be relieved with antihistamine sprays. They are available by prescription and include azelastine (Astelin, Astepro) and olopatadine (Patanase).

The global burden of respiratory diseases such as allergic rhinitis, chronic obstructive pulmonary disease, asthma has increased rapidly in the last three decades. In an article published in NCBI, it was reported that around 20–30 % of the Indian population suffers from allergic rhinitis and that 15 % develop asthma.

Due to this growing burden, there has been an increased adoption rate of nasal antihistamines in the form of nasal sprays and nasal drops, globally. The nasal antihistamines provide rapid and effective relief from the symptoms of allergic rhinitis. Thus, the growing number of allergic rhinitis cases will propel the growth of the nasal antihistamines market in the future.

Advancements in the field of nasal drug delivery have enabled the establishment of several non-invasive approaches for treatment. Various new products such as metered dose delivery systems, innovative odorless powders and sprays, preservative-free nasal sprays and others are key drivers that will expand this industry in the forecast period.

FDA approvals of various nasal sprays to switch from prescription to OTC use has led to increased independence concerning self-administration of drugs, amongst patients who suffer from allergic rhinitis. Various additions by the manufacturers to the already available product lines, especially for AR are some of the techniques used by the manufacturers to increase product penetration amongst the population.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-13708

New product launches & approvals have emerged as key growth strategies adopted by the leading players in the nasal antihistamines market. Followed by this, the acquisition was the second most key strategy adopted by the industry players. By adopting these strategies, it helped the company to expand their regional presence as well as product offerings.

For instance, In December 2020, GlaxoSmithKline launched Otrivin Breathe clean, a saline wash with the moisturizing benefit of natural glycerine as a product for the symptomatic relief of allergic rhinitis.

Such developments not only strengthens the company’s existing portfolio but also help to increase their presence at the regional as well as global level, and helps companies to sustain the increasing competitive pressure.

Key Takeaways from Nasal Antihistamines Market Study

  • By pProduct, nasal sprays accounted for the largest share of 89.0% in 2021 and are expected to continue to grow at the same trend during the forecast period.
  • By age group, adults accounted for the largest share in 2021 of the nasal antihistamines market and are expected to continue to grow at the same trend during the forecast period.
  • By distribution channel, the retail pharmacies segment is expected to account for the largest share of 41.0% in 2021 of the nasal antihistamines market and is expected to continue to grow at the same trend during the forecast period.
  • By region, East Asia held the largest share of 23.0% in 2021 of the nasal antihistamines market. The growing awareness regarding allergies and developing healthcare infrastructure are some of the factors that fuel the high market share of this region.

Who is Winning?

Some of the leading manufacturers of the nasal antihistamines market are focusing on product launch collaboration and partnership strategies for global expansion objectives, thereby, enhancing their market presence.

  • In April 2021, Merck & Co. acquired Pandion Therapeutics, Inc which is a U.S. based clinical-stage biotechnology company for US $ 1.85 Bn. With this acquisition, Merck strategizes to identify and secure candidates with differentiated and potentially found characteristics for the clinical trials that would be required for their new product launches. This will ensure smooth conduction of clinical trials and thus help the company to expand their business.
  • In April 2020, Cipla receives final approval for a generic version of Proventil® HFA Inhalation Aerosol, from the United States FDA. With this approval, the company strengthened their presence in the US pharmaceutical market

The key market players covered by FMI include Bayer Healthcare LLC, Novartis International AG, Cipla, Glenmark Pharmaceuticals, GlaxoSmithKline, Sun Pharmaceuticals, Merck & Co., Centaur Pharmaceuticals, Viatris (Meda Pharmaceuticals), Proctor & Gamble, Ascend Laboratories LLC (Alkem Laboratories), J Pharmaceuticals, Alitair Pharmaceuticals and Sato Pharmaceuticals.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-13708

Nasal antihistamines by Category Product:

  • Nasal Spray
  • Nasal Drops

Age Group:

  • Adult
  • Pediatric

Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Stores

Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East and Africa (MEA)

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 9-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedInTwitterBlogs

Americas COVID-19 Testing Market Key Players – Aurora Instruments Ltd., PRIMA Lab SA, Sky Medical Supplies & Equipment LLC., Sugentech, Inc.,

[200 Pages Report] The market is set to expand due to frequent mutations in the virus that may lead to further outbreaks. Leading organizations within the market are set to focus on research and development to offer an early and precise diagnosis of the COVID-19, besides offering effective patient care.

Some of the leading players in the Americas COVID-19 testing market include but are not limited to Sky Medical Supplies & Equipment LLC., Sugentech, Inc., Novacyt Group, Aurora Instruments Ltd., PRIMA Lab SA, SD Biosensor, INC., Gold Standard Diagnostics, Eurofins Technologies, Biomerieux SA, and Danaher.

According to Future Market Insights (FMI), the demand for COVID-19 testing is expected to reach a valuation of US$ 4,507.8 Mn in the Americas by the end of 2021. The pandemic is spreading on a global scale at a very high pace. It can cause various health concerns including cardiovascular diseases, kidney failure, and more.

To overcome the problems related to COVID-19, it is important to diagnose the ailment at an early stage of infection. According to the World Health Organization (WHO), more than 180 million positive cases of COVID-19 were diagnosed till June 2021. The rate of positive cases can be controlled with early diagnosis and treatment.

SARS-CoV-2 antigen rapid test kits are the most common type of test that accounted for value USD 2,903.0 Mn in 2020. It is widely accepted due to convenience, ease and rapid nature in the diagnosis process.

The demand for point of care testing is increasing due to advantages such as lower time requirements, at home services, and cost effectiveness. These factors are going to bolster the demand for point of care testing during the forecast period. For instance, on 28 July 2020, Roche announced the launch of the SARS-CoV-2 Rapid Antibody Test in collaboration with SD Biosensor Inc.

With the launch of vaccines and development of mass vaccination programs by governments, the number of COVID-19 cases is expected to drop by the end of 2021, however, it is expected that testing will continue even as lockdown in many countries will be lifted. Key players are focused on strengthening their mergers and acquisitions with new discoveries of technologies.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-13636

Key Takeaways from COVID-19 Testing Services Market Study

  • SARS-CoV-2 antigen rapid test kits are expected to account for over 67% the Americas COVID-19 testing market share by 2031, owing to higher efficacy in diagnostics.
  • Hospital pharmacies accounted for more than 32% of the market share in 2021. The soaring influx of patients for treatment and intensive care support has driven growth.
  • Canada will reflect relatively steady growth with a 4.8% CAGR, driven by the matured, government funded healthcare system.
  • The U.S. will reflect fast growth at a CAGR around 5.7% through 2021-2031. U.S. holds the lead owing to, high healthcare expenditure, and the presence of leading players.
  • Brazil is the leading country in Latin America, estimated to account for about 54% of the regional share in 2021, supported by easier access to required technologies.

“The shift in focus from testing to vaccination is expected to hamper market growth in the near future. However, the focus on testing for international travel, frequent testing of medical staff and testing for patients with flu like symptoms are expected to continue aiding market growth,” says the Future Market Insight analyst.

Want More Insights?

Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031. The global COVID-19 testing market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on the COVID-19 testing treatment market on basis of the test type in detail, cover every aspect of the market such as Test type, sample type, distribution channel across North America and Latin America region.

Americas COVID-19 testing Market by CategoryTest Type:

  • SARS-CoV-2 IgM/IgG Antibody Rapid Test Kits
  • SARS-CoV-2 Antigen Rapid Test Kits
  • Multiplex Real-Time RT-PCR Assay Kits

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-13636

Sample Type:

  • Blood
  • Nasopharyngeal Swabs

Distribution Channel:

  • Hospital Pharmacies
  • Diagnostic Laboratories
  • Retail Pharmacies
  • Drug Store
  • Online Sales Channels

Region:

  • North America
  • Latin America

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports : https://www.futuremarketinsights.com/reports
LinkedInTwitterBlogs

Microneedle Drug Delivery Systems Market Key Players – Nanopass Tech, 3M Company, Becton, Dickinson and Company, Zosano Pharma Corporation

Emerging applications of microneedle drug delivery systems are expected to fuel their demand over the next decade. According to a recent report published by Future Market Insights (FMI), the global microneedle drug delivery systems market will grow at a CAGR of 6.6% between 2020 and 2030. The market is witnessing surging demand in the field of pharmacy and cosmetics.

The rising incidence of diseases such as cancer, diabetes, migraine, and others and the need to accurately administer medications are driving the market. Additionally, the demand for minimally invasive and painless treatment methods is expected to bode well for the market.

The report uncovers hidden growth opportunities. It also highlights potential threats to the market players. Some of the key takeaways from the report are highlighted below.

Request Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-2750

Key Takeaways from the Report

  • Solid microneedles are expected to lead the market during forecast period of 2020-2030 among product type
  • Hospitals are the leading end users of microneedle drug delivery systems, with specialty clinics gaining popularity.
  • Specialty clinics are expected to grow at an accelerated rate as one of the key end users of microneedle drug delivery systems
  • North America is the largest market for microneedle drug delivery systems. Along with Europe, it is expected to cover more than 70% of the market by end of 2030.
  • East Asia is expected to be the fastest growing regional market during the next decade.

“Companies operating in the market are leaving no stone unturned to introduce innovations. Some have even tied up with leading solutions provider to commercialize their innovations once approved. This is expected to pave way for the market’s growth in the near future” said a lead Analyst at FMI.  

Covid 19 Restricting Pace of Growth

The onset of pandemic has disturbed the entire business ecosystem. With productions coming to a halt and supply chains disrupted due to lack of transport, manufacturers of microneedle drug delivery systems are impacted in a big way.

Also, because of several restrictions by governments like social distancing, doctors and practitioners are choosing to avoid any surgical treatments which are not absolutely and immediately necessary.

Furthermore, cosmetic field which is another major user of microneedle drug delivery systems is also impacted as almost all treatments under their umbrella are considered to be not urgent.

Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-2750

The key market players in microneedle drug delivery systems market include the

3M Company, Becton, Dickinson and Company, Zosano Pharma Corporation, Raphas co. ltd., Nanopass Tech, Corium International, Inc., Valeritas, Inc., Nitto Denko Corporation, Microdermics, Inc., TheraJect Inc., Vaxxas Pty Ltd., Endoderma Ltd., QuadMedicine, SNvia Co., Ltd., Small Lab and AdminMed Nano BioSciences LLC

Consolidating their positions through mergers, acquisitions and new product launches, global microneedle drug delivery systems market players rely heavily on new product innovation and differentiation for gaining an edge over their competitors.

The market is poised to grow during the forecast period owing to the increasing cases of diseases and needle phobia among patients. However, changing regulatory dynamics are expected to affect the growth of microneedle drug delivery systems market in the future.

For instance, Zosano Pharma’s clinical trial of zolmitriptan with microneedle drug delivery system was stopped by U. S. Food and Drug Administration because inconsistencies were found in the drug delivery.

To Know More about Heat induction Cap liner Market:

Future Market Insights (FMI) brings the comprehensive research report on forecast revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2015 to 2030. The global microneedle drug delivery systems market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on microneedle drug delivery systems market on the basis of product type such as solid microneedles, hollow microneedles and dissolving microneedles. Based on end-user such as hospitals, ambulatory centers, specialty clinics, academic institutes and research institutes across seven major regions

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-2750 

Key Segments

Product Type

  • Solid Microneedles
    • Silicon
    • Metal
    • Polymer
  • Hollow Microneedles
  • Dissolving Microneedles

End User

  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Clinics
  • Academic Institutions
  • Research institutes

Region

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • MEA

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedInTwitterBlogs

Feminine Hygiene Products Market is likely to surpass US$ 54,189.6 Mn by 2031

Government initiatives undertaken to spread awareness about women health and menstrual hygiene, besides brand consolidation strategies by leading producers and the adoption of modern lifestyles by women will push feminine hygiene products sales in the coming years.

According to the recent Future Market Insights (FMI) report, the global feminine hygiene products market value is estimated to surpass US$ 27.6 Bn in 2021, with a CAGR of 7.0% during the forecast period (2021-2031).

Around 49% of the global population is female and nearly 65% of them are aged between 15 and 65 years, thereby indicating a significant opportunity for manufacturers of feminine hygiene products.

Government organizations are focusing on women’s health and hygiene with the help of launch of various awareness programs and funding activities. These programs include detailed education about menstruation, puberty, and the advantages and health benefits of using hygiene products.

They are also providing sanitation kits to girls studying in government schools and colleges in rural areas, particularly in developing economies around the globe. For instance, in 2017, the Department of Education in KwaZulu-Natal (KZN) of South Africa set aside Rs 50 million to fund the distribution of sanitary towels and napkins to various schools in the region.

Request a sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-13350

Additionally, rising female populations in countries such as India, Ghana, and Nigeria will create lucrative opportunities. Concerns regarding disposal, have resulted in the introduction of reusable menstrual cups. These cups are made from medical grade silicon or latex and cost between US$ 20 and US$ 50 per pack and can last for nearly five years. Such innovations will give tailwinds to growth registered in the market.

The impact of the ongoing COVID-19 pandemic on production of feminine products has been negligible despite short term disruptions of transportation and logistics.

Key Takeaways from Feminine Hygiene Products Market Study

  • Sanitary napkins are the largest and fastest growing segment accounting for nearly half of the market by 2031, with a CAGR of over 8%.
  • Supermarket are projected to account for over 22% of the global market by 2031. This is attributed to robust supply channels for consumer health products.
  • East Asia is the largest revenue-generating region for feminine hygiene products, with the China accounting for nearly 81% of the regional market in 2021.
  • Germany holds the lead in Europe, and is expected to accounting for over 18% of the market in 2031.
  • South Asia is the second most lucrative market after East Asia with India accounting for over 75% of the value share in 2031.

 Request a TOC@ https://www.futuremarketinsights.com/toc/rep-gb-13350

Who is Winning?

Some of the leading manufacturers of the feminine hygiene products market are focusing on mergers and acquisitions for global expansion. Thus, enhancing their market presence.

The key market players covered by FMI include Procter and Gamble, Johnson and Johnson, the Kimberly-Clark Corporation, Svenska Cellulosa Aktiebolaget SCA, Sanofi S.A, Lil-lets UK Limited, Ontex, Unicharm Corporation, Diva International Inc., and Edgewell Personal Care.

Why Future Market Insights?

• Comprehensive analysis on evolving purchase pattern across different geographies
• Detailed insights of market segments and sub-segments for historical as well as forecast period
• A competitive analysis of prominent players and emerging players in the keyword market
• Detailed information about the product innovation, mergers and acquisitions lined up in upcoming years

Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario

Ask An expert here @ https://www.futuremarketinsights.com/askus/rep-gb-13350

Feminine Hygiene Products Market by Category

Product type:

  • Sanitary Napkins
  • Tampons
  • Menstrual Cup
  • Panty liners
  • Feminine Hygiene Wash

Distribution Channel:

  • Hypermarket
  • Supermarket
  • Convenience Stores
  • Department Stores
  • Retail Pharmacies
  • Online Purchase

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Unit No: 1602-006
Jumeirah Bay 2
Plot No: JLT-PH2-X2A
Jumeirah Lakes Towers
Dubai
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedInTwitterBlogs